---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-042474"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T12:12:34.702010+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tivic Health Q2 revenue down 70% to $161K, net loss improves, approves reverse split

## Summary
- Q2 revenue $161K (down 70% YoY); net loss $2.1M (from $3.0M).
- Gross margin rose to 37.5% on price increases and cost cuts.
- Cash $2.7M at June 30; raised $4.8M net via stock sales July–Aug.
- Stockholders approved reverse stock split (1:5 to 1:100) to meet Nasdaq minimum bid.
- Signed Cardinal Health distribution deal; started Feinstein pilot for vagus nerve therapy.

## SEC filing metadata
- accession: 0000950170-23-042474
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017023042474/0000950170-23-042474-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017023042474/tivc-20230811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-042474
- JSON: https://secwatch.observer/filing/0000950170-23-042474.json
- Plain text: https://secwatch.observer/filing/0000950170-23-042474.txt

## Key facts
- Earnings Releases
  Valion Bio, Inc. reported the second quarter 2023 ended June 30, 2023 ("Q2 2023") results: revenue $60 thousand, net income Net loss of $2.1 million.
  - Period: the second quarter 2023 ended June 30, 2023 ("Q2 2023")
  - Revenue: $60 thousand
  - Net income: Net loss of $2.1 million
  - Result: reported results
  source text: Tivic Reports Second Quarter 2023 Financial Results SAN FRANCISCO – (Business Wire) – August 14, 2023 – Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced its financial results for the second quarter 2023 ended June 30, 2023 (“Q2 2023”). Second Quarter 2023 Financial Summary • Gross profit of 37.5% in the second quarter 2023, compared to 23.4% in second quarter 2022, on total revenue of $60 thousand in the second quarter 2023 from $123 thousand in second quarter 2022. • Net loss of $2.1 million in the second quarter 2023, compared with $3.0 million in second quarter 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000095017023042474/0000950170-23-042474-index.htm
- Shareholder Votes
  Valion Bio, Inc. shareholders approved Proposal to authorize the Board to amend the certificate of incorporation to effect a reverse stock split at a ratio of not less than 1-for-5 and not greater than 1-for-100. at the 2023-08-11 meeting.
  - Proposal: reverse split
  - Outcome: passed
  - Meeting: 2023-08-11
  source text: Proposal No. 1: The Company’s stockholders approved the Company’s proposal to authorize the Company to amend its amended and restated certification of incorporation to effect, at the discretion of its board of directors (the “Board”), a reverse stock split of all of the Company’s issued and outstanding shares of common stock at a ratio of not less than 1-for-5 and not greater than 1-for-100, such ratio to be determined by its Board at any time within twelve months, without further approval or authorization of its stockholders. The final voting results as follows: Votes For Votes Against Abstentions Broker Non-Votes 32,939,351 797,381 2,550,259 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000095017023042474/0000950170-23-042474-index.htm
- Shareholder Votes
  Valion Bio, Inc. shareholders approved Proposal to authorize the Board to adjourn the Special Meeting to solicit additional proxies. at the 2023-08-11 meeting.
  - Outcome: passed
  - Meeting: 2023-08-11
  source text: Proposal No. 2: The Company’s stockholders approved the Company’s proposal to authorize the Board, in its discretion, to adjourn the Special Meeting to another place, or a later date or dates, if necessary or appropriate, to solicit additional proxies in favor of Proposal No. 1 at the time of the Special Meeting. The final voting results as follows: Votes For Votes Against Abstentions Broker Non-Votes 32,903,493 723,184 2,660,314 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000095017023042474/0000950170-23-042474-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.